Novan (FRA:6LUA) FCF Margin % : -142.60% (As of Mar. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Novan FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Novan's Free Cash Flow for the three months ended in Mar. 2023 was €-3.99 Mil. Novan's Revenue for the three months ended in Mar. 2023 was €2.80 Mil. Therefore, Novan's FCF Margin % for the quarter that ended in Mar. 2023 was -142.60%.

As of today, Novan's current FCF Yield % is 0.00%.

The historical rank and industry rank for Novan's FCF Margin % or its related term are showing as below:

FRA:6LUA' s FCF Margin % Range Over the Past 10 Years
Min: -159.41 Med: 0 Max: 0
Current: -159.41

FRA:6LUA's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -139.2 vs FRA:6LUA: -159.41

Novan FCF Margin % Historical Data

The historical data trend for Novan's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novan FCF Margin % Chart

Novan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-496.28

-453.41

-753.51

-1,198.92

-148.91

Novan Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
FCF Margin %	Get a 7-Day Free Trial															-8.56	-210.98	-193.03	-116.28	-142.60

Competitive Comparison of Novan's FCF Margin %

For the Biotechnology subindustry, Novan's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novan's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novan's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Novan's FCF Margin % falls into.

Novan FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Novan's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-33.188	/	22.287
	=	-148.91 %

Novan's FCF Margin for the quarter that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-3.99	/	2.798
	=	-142.60 %

Novan FCF Margin % Related Terms

Thank you for viewing the detailed overview of Novan's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novan (FRA:6LUA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novan Inc (FRA:6LUA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NOVNQ:USA

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

Novan (FRA:6LUA) Headlines

No Headlines